Evidence map›Paper›PMID 26739108›Full record

ArticleCellular signalling2016

ERK5 induces ankrd1 for catecholamine biosynthesis and homeostasis in adrenal medullary cells.

Yutaro Obara, Ryusuke Nagasawa, Wataru Nemoto, Michael J Pellegrino, Maho Takahashi, Beth A Habecker, Philip J S Stork, Osamu Ichiyanagi, Hiromi Ito, Yoshihiko Tomita and 2 more

Open access · greenAbstract read
In one paragraph

Article in Cellular signalling, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Trojan Horse Delivery of 4,4'-Dimethoxychalcone for Parkinsonian Neuroprotection.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
  9. Article
  10. Article
  11. Midnolin is a confirmed genetic risk factor for Parkinson's disease.Annals of clinical and translational neurology · 2019
    Article
  12. ERK5 Phosphorylates KInternational journal of molecular sciences · 2018
    Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Yutaro ObaraDepartment of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba 6-3, Aramaki, Aoba-ku, Sendai 980-8578, Japan; Department of Pharmacology, Yamagata University School of Medicine, Iida-Nishi 2-2-2, Yamagata 990-9585, Japan. Electronic address: obaray@med.id.yamagata-u.ac.jp.
Ryusuke NagasawaDepartment of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba 6-3, Aramaki, Aoba-ku, Sendai 980-8578, Japan.
Wataru NemotoDepartment of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba 6-3, Aramaki, Aoba-ku, Sendai 980-8578, Japan.
Michael J PellegrinoDepartment of Physiology and Pharmacology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, USA.
Maho TakahashiThe Vollum Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, USA.
Beth A HabeckerDepartment of Physiology and Pharmacology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, USA.
Philip J S StorkThe Vollum Institute, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239-3098, USA.
Osamu IchiyanagiDepartment of Urology, Yamagata University School of Medicine, Iida-Nishi 2-2-2, Yamagata 990-9585, Japan.
Hiromi ItoDepartment of Urology, Yamagata University School of Medicine, Iida-Nishi 2-2-2, Yamagata 990-9585, Japan.
Yoshihiko TomitaDepartment of Urology, Yamagata University School of Medicine, Iida-Nishi 2-2-2, Yamagata 990-9585, Japan.
Kuniaki IshiiDepartment of Pharmacology, Yamagata University School of Medicine, Iida-Nishi 2-2-2, Yamagata 990-9585, Japan.
Norimichi NakahataDepartment of Cellular Signaling, Graduate School of Pharmaceutical Sciences, Tohoku University, Aoba 6-3, Aramaki, Aoba-ku, Sendai 980-8578, Japan.
Yamagata University · JPOregon Health & Science University · USTohoku University · JPVollum Institute · US

Funding

Neurotrophins and post-infarct plasticity in cardiac sympathetic neuronsR01HL093056 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI BETH A HABECKER · 2009 to 2026
$7.9M
Regulation of Sympathetic Function by InfarctionR01HL068231 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI HABECKER, BETH A · 2001 to 2015
$4.3M
NHLBI NIH HHS R01 HL068231NHLBI NIH HHS R01 HL093056
6 · The paper itself

Abstract

Extracellular signal-regulated kinases (ERKs) play important roles in proliferation, differentiation and gene expression. In our previous study, we demonstrated that both ERK5 and ERK1/2 were responsible for neurite outgrowth and tyrosine hydroxylase (TH) expression in rat pheochromocytoma cells (PC12) (J Biol Chem 284, 23,564-23,573, 2009). However, the functional differences between ERK5 and ERK1/2 signaling in neural differentiation remain unclear. In the present study, we show that ERK5, but not ERK1/2 regulates TH levels in rat sympathetic neurons. Furthermore, microarray analysis performed in PC12 cells using ERK5 and ERK1/2-specific inhibitors, identified ankyrin repeat domain 1 (ankrd1) as an ERK5-dependent and ERK1/2-independent gene. Here, we report a novel role of the ERK5/ankrd1 signaling in regulating TH levels and catecholamine biosynthesis. Ankrd1 mRNA was induced by nerve growth factor in time- and concentration-dependent manners. TH levels were reduced by ankrd1 knockdown with no changes in the mRNA levels, suggesting that ankrd1 was involved in stabilization of TH protein. Interestingly, ubiquitination of TH was enhanced and catecholamine biosynthesis was reduced by ankrd1 knockdown. Finally, we examined the relationship of ERK5 to TH levels in human adrenal pheochromocytomas. Whereas TH levels were correlated with ERK5 levels in normal adrenal medullas, ERK5 was down-regulated and TH was up-regulated in pheochromocytomas, indicating that TH levels are regulated by alternative mechanisms in tumors. Taken together, ERK5 signaling is required for catecholamine biosynthesis during neural differentiation, in part to induce ankrd1, and to maintain appropriate TH levels. This pathway is disrupted in pathological conditions.

Indexed as

AdolescentAdrenal Gland NeoplasmsAdultAgedAged, 80 and overAnimalsCatecholaminesChromatography, High Pressure LiquidDown-RegulationFemaleHumansMaleMicroscopy, FluorescenceMiddle AgedMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Ankrd1 protein, ratCatecholaminesMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3Mitogen-Activated Protein Kinase 7Muscle ProteinsNerve Growth FactorNuclear ProteinsRepressor ProteinsRNA, Small InterferingTyrosine 3-MonooxygenaseAnkyrin repeat domain 1 (ankrd1)Extracellular-signal regulated kinase (ERK)Nerve growth factor (NGF)PheochromocytomaSympathetic neuronsTyrosine hydroxylase (TH)

Identifiers

PMID26739108
PMCPMC6521842
OpenAlexW2212528925

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.